Targets of SARS-CoV-2: Therapeutic implications for COVID-19

R Chadha, A Raghav, B Banerjee, A Sengar, M Sengar… - Stem Cells, 2024 - Elsevier
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its
subsequent manifestation as coronavirus disease-2019 (COVID-19) marked a global health …

Activation of Ang-(1-7)/Mas receptor is a possible strategy to treat coronavirus (SARS-CoV-2) infection

GS Magalhaes, MG Rodrigues-Machado… - Frontiers in …, 2020 - frontiersin.org
Coronavirus disease (COVID)-19 is developed from the virus entering the host cells, initially
in the airways, mouth, eyes, and lungs. The cell membrane of these tissues expresses, with …

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

R Poduri, G Joshi, G Jagadeesh - Cellular signalling, 2020 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense,
single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract …

Therapeutic potential of the purinergic system in major depressive disorder associated with COVID-19

JLB Simões, ACL Galvan, ELM da Silva… - Cellular and Molecular …, 2023 - Springer
Neuroinflammation is closely related to the development of depression, since the latter is
caused, among other factors, by inflammatory processes, mainly related to the activation of …

A comprehensive review on potential therapeutics interventions for COVID-19

H Chugh, A Awasthi, Y Agarwal, RK Gaur… - European Journal of …, 2021 - Elsevier
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, a new beta
coronavirus that emerged in Wuhan, China. Being primarily a respiratory disease, it is highly …

Purinergic signaling of ATP in COVID-19 associated Guillain-Barré syndrome

JLB Simões, MD Bagatini - Journal of Neuroimmune Pharmacology, 2021 - Springer
Declared as a global public health emergency, coronavirus disease 2019 (COVID-19) is
presented as a disease of the respiratory tract, although severe cases can affect the entire …

Effects of purinergic receptor deletion or pharmacologic modulation on pulmonary inflammation in mice

GS Whitehead, TP Karcz, DK Tosh… - ACS Pharmacology & …, 2022 - ACS Publications
COVID-19 disease is associated with progressive accumulation of SARS-CoV-2-specific
mRNA, which is recognized by innate immune receptors, such as TLR3. This in turn leads to …

Activation of the cholinergic anti-inflammatory pathway as a novel therapeutic strategy for COVID-19

Z Qin, K Xiang, DF Su, Y Sun, X Liu - Frontiers in Immunology, 2021 - frontiersin.org
The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for
alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory …

Can beta-2-adrenergic pathway be a new target to combat Sars-Cov-2 hyperinflammatory syndrome?—lessons learned from cancer

A Barbieri, N Robinson, G Palma, N Maurea… - Frontiers in …, 2020 - frontiersin.org
SARS-CoV-2 infection is a new threat to global public health in the 21st century (2020),
which has now rapidly spread around the globe causing severe pneumonia often linked to …

Severe acute respiratory syndrome coronavirus-2 induces cytokine storm and inflammation during coronavirus disease 19: perspectives and possible therapeutic …

F Mannino, A Bitto, N Irrera - Frontiers in Pharmacology, 2020 - frontiersin.org
The new coronavirus outbreak was first identified in Wuhan, China, in December 2019, and
has turned out to be a global health emergency, affecting millions of people worldwide …